Results 11 to 20 of about 9,895 (133)

Transcatheter Tricuspid Valve Replacement for Residual Tricuspid Regurgitation After TEER. [PDF]

Catheter Cardiovasc Interv
ABSTRACT Background Residual or recurrent tricuspid regurgitation (TR) after prior transcatheter tricuspid edge‐to‐edge (T‐TEER) repair occurs in about 12% of patients within 1 year. Since surgical tricuspid valve repair or replacement is of high risk, treatment options remain scarce.
Voß F, Mourikis P, Nienhaus F, Haschemi J, Hoss A, Zeus T, Kowalski H, Spieker M, Jung C, Horn P, Aubin H, Lichtenberg A, Truse R, Kelm M, Polzin A.   +14 more
europepmc   +2 more sources

Transcatheter tricuspid valve interventions: Current status and future perspectives

Frontiers in Cardiovascular Medicine, 2022
The development of transcatheter therapies to treat valvular heart diseases has changed the rules of the game, particularly in the case of aortic stenosis and mitral regurgitation.
Alberto Alperi, Alberto Alperi, Marcel Almendárez, Marcel Almendárez, Rut Álvarez, Rut Álvarez, Cesar Moris, Cesar Moris, Cesar Moris, Victor Leon, Victor Leon, Iria Silva, Iria Silva, Daniel Hernández-Vaquero, Daniel Hernández-Vaquero, Daniel Hernández-Vaquero, Isaac Pascual, Isaac Pascual, Isaac Pascual, Pablo Avanzas, Pablo Avanzas, Pablo Avanzas   +21 more
doaj   +1 more source

Rediscovered and Unforgotten: Transcatheter Interventions for the Treatment of Severe Tricuspid Valve Regurgitation

US Cardiology Review, 2021
Tricuspid valve regurgitation is both globally prevalent and undertreated. Historically, surgical intervention for isolated tricuspid regurgitation (TR) was avoided despite the prevalence of TR, largely due to poor surgical outcomes and an incomplete ...
Kusha Rahgozar, Sharon Bruoha, Edwin Ho, Ythan Goldberg, Mei Chau, Azeem Latib   +5 more
doaj   +1 more source

Transcatheter Tricuspid Valve Intervention: Current Perspective

US Cardiology Review, 2021
Tricuspid regurgitation (TR) adversely impacts both quality of life and long-term survival, which generates interest in therapeutic approaches to mitigate these effects.
Trevor J Simard, Mackram F Eleid
doaj   +1 more source

Transcatheter Tricuspid Valve-In-Ring and Aortic Valve-In-Valve Implantation

The Thoracic & Cardiovascular Surgeon Reports, 2017
Background Transcatheter heart valve (THV) therapies have shown to be an alternative to surgical valve replacement, especially in high-risk patients requiring redo surgery. However, reports of transcatheter-based interventions in tricuspid valve position
Daniel Reichart, Niklas Schofer, Florian Deuschl, Andreas Schaefer, Stefan Blankenberg, Hermann Reichenspurner, Ulrich Schaefer, Lenard Conradi   +7 more
doaj   +1 more source

Outcomes of minimally invasive isolated tricuspid valve reoperation after left-side valve surgery: A single-center experience

Frontiers in Cardiovascular Medicine, 2023
BackgroundLate severe tricuspid regurgitation (TR) after left-side valve surgery (LSVS) is not uncommon. However, the tricuspid valve has been deemed the forgotten valve because the isolated TR is well tolerated with medication, and reoperation has a ...
Jian Liu, Jian Liu, Tong Tan, Tong Tan, Tong Tan, Huanlei Huang, Huanlei Huang, Wenda Gu, Wenda Gu, Xin Zang, Xin Zang, Jianrui Ma, Jianrui Ma, Jianrui Ma, Hongxiang Wu, Hongxiang Wu, Haozhong Liu, Haozhong Liu, Haozhong Liu, Jian Zhuang, Jian Zhuang, Jimei Chen, Jimei Chen, Huiming Guo, Huiming Guo   +24 more
doaj   +1 more source

The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China

Frontiers in Cardiovascular Medicine, 2023
BackgroundData on outcomes following transcatheter aortic valve replacement with SAPIEN 3 in China is limited as it was approved by the National Medical Products since 2020.
Xiaoke Shang, Xiangbin Pan, Gejun Zhang, Zhengming Jiang, Xianbao Liu, Guangyuan Song, Yi Li, Yan Wang, Jianfang Luo, Yida Tang, Yiqiang Yuan, Yongjian Wu, Xiang Ma, Dan Zhu, Yucheng Zhong, Changdong Zhang, Nianguo Dong   +16 more
doaj   +1 more source

Percutaneous Transcatheter Valve-in-Valve Pulmonary and Tricuspid Replacement in Carcinoid Heart Disease

JACC: Case Reports, 2020
Surgical valve replacement is the most effective treatment for carcinoid heart disease; however, reoperation for prosthetic valve failure is burdened by high risk.
Suvitesh Luthra, MD, Carlo Olevano, MD, Trevor Richens, MD, Geoff M. Tsang, MD   +3 more
doaj   +1 more source

Transcatheter Tricuspid Valve Replacement: Principles and Design

Frontiers in Cardiovascular Medicine, 2018
Tricuspid regurgitation (TR) may affect as much as 65–85% of the population with the prevalence of moderate-to-severe TR in the United States reported at greater than 1.6 million.
Ozan M. Demir, Ozan M. Demir, Damiano Regazzoli, Antonio Mangieri, Marco B. Ancona, Satoru Mitomo, Giora Weisz, Antonio Colombo, Azeem Latib, Azeem Latib   +9 more
doaj   +1 more source

Sex Differences in Transcatheter Structural Heart Disease Interventions: How Much Do We Know?

Cardiovascular Innovations and Applications, 2023
The number of structural heart disease interventions has greatly increased in the past decade. Moreover, interest in the sex-specific outcomes of various cardiovascular conditions and procedures has increased.
Lina Ya’Qoub, Jelena Arnautovic, Nadeen N. Faza, Islam Y. Elgendy   +3 more
doaj   +1 more source